ARTICLE | Finance
Back for more
Why Moderna's valuation is at an all-time high
September 12, 2016 7:00 AM UTC
Less than a year after big funds including Fidelity slashed their valuations of Moderna Therapeutics Inc., the firms are buying more of the mRNA therapeutics developer in a stepped-up round.
Last week, Moderna raised $474 million in a venture round with at least 72 participants. These included Fidelity, Wellington and other existing institutional investors, as well as the company's pharma partners and new institutional investors...